The objective of this research is to explore the impact of AT1RB therapy on depression and anxiety‐like behaviors triggered by menopause, as well as the levels of NLRP3, IL‐1β, BDNF, and oxidative stress in the hippocampal and prefrontal cortex tissues. The gene discussed is NLRP3; the disease is major depressive disorder.